Skip to main content
Premium Trial:

Request an Annual Quote

Proteome Sciences Retained by Siena Biotech for Biomarker Services

NEW YORK (GenomeWeb News) – Siena Biotech has retained Proteome Sciences under a Master Research Agreement to supply protein and peptide biomarkers services for its drug discovery programs, Proteome announced today.

The UK-based proteomics firm added that as the first project under the agreement it will apply its PS Biomarkers services to analyze post-translational modifications on a neurological disease-related protein. Using its sample preparation and analytical methods in combination with Thermo Fisher Scientific's Orbitrap Velos mass spectrometry, Proteome will "deliver a high-density PTM map of Siena Biotech's protein target."

Such maps can confirm proof of disease mechanism and/or mode of action of targeted therapeutics to help a drug firm decide whether to proceed with further development, Proteome said.

Financial and other terms of the deal were not disclosed.

Siena Biotech is a clinical-stage drug development firm based in Italy.

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.